Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Open-label, Multi-centre, Extension Study to Explore the Long-term Safety and Efficacy of KH176 in Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation Who Have Completed the KHENERGYZE Study KH176-202.

NCT04604548 is registered in ClinicalTrials.gov with Khondrion BV as lead sponsor.

NCT NCT04604548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04604548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Open-label, Multi-centre, Extension Study to Explore the Long-term Safety and Efficacy of KH176 in Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation Who Have Completed the KHENERGYZE Study KH176-202.
Lead sponsor
Khondrion BV
Phase
Phase 2
Overall status
Completed
Start date
August 9, 2021
Completion date
June 1, 2023
Enrollment
11 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic progressive external ophthalmoplegia (cpeo), maternally inherited diabetes and deafness (midd), mitochondrial diseases, mitochondrial dna trnaleu(uur) m.3243a<g mutation, mitochondrial encephalomyopathy, lactic acidosis and stroke like episodes (melas)